申请人:ALNYLAM PHARMACEUTICALS, INC.
公开号:US20180135057A1
公开(公告)日:2018-05-17
The invention relates to antisense polynucleotide agents targeting the LECT2 gene, and methods of using such antisense polynucleotide agents to inhibit expression of LECT2 and to treat subjects having a LECT2-associated disease, e.g., amyloidosis.
这项发明涉及针对LECT2基因的反义多核苷酸药剂,以及利用这种反义多核苷酸药剂抑制LECT2表达并治疗患有LECT2相关疾病(例如淀粉样变性)的受试者的方法。